Health Trials

About this trial

The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.

Eligibility criteria

Qualifiers

Age 18 years and older

Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1/FVC < 0.7)

Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD)

Inclusion within 48 hours post hospital admission

Disqualifiers

Patients unwilling or unable to comply with study procedures

Patients not requiring treatment with systemic corticosteroids, antibiotics or both as a minimum therapy for the index AECOPD

Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

22
Austria
Kepler University Hospital Linz Austria
University Hospital Vienna Vienna Austria
Belgium
CHU St-Pierre Brussels1000, Brussels Belgium
UZ Leuven3000, Leuven Belgium

Sponsors and collaborators

Wim Janssens

Lead sponsor

KU Leuven

Sponsor institution

European Respiratory Society

Collaborator

AstraZeneca

Collaborator

Roche Pharma AG

Collaborator

GlaxoSmithKline

Collaborator

Source ClinicalTrials.gov